About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals is a company based in Watertown (United States) founded in 2006 was acquired by La Jolla Pharmaceutical in June 2020. Tetraphase Pharmaceuticals has raised $80.04 million across 5 funding rounds from investors including La Jolla Pharmaceutical, Flagship Pioneering and Excel Venture Management. The company has 31 employees. Tetraphase Pharmaceuticals operates in a competitive market with competitors including Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others.
- Headquarter Watertown, United States
- Employees 31
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website tphase.com
- Social LinkedIn X Facebook
- Acquired by La Jolla Pharmaceutical (Jun 2020)
- Total Equity Funding$80.04M (USD)
in 5 rounds
- Latest Funding Round$10M (USD), Post-IPO
Jan 2020
- InvestorsLa Jolla Pharmaceutical
& 7 more
- Employee Count31
- Acquired byLa Jolla Pharmaceutical
(Jun 2020)
Funding Insights of Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals has successfully raised a total of $80.04M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $10 million completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $80.04M
- Total Rounds 5
- Last Round Post-IPO — $10M
- First Round $10.04M
(Nov 2006)
- Investors Count 7
All 5 funding rounds of Tetraphase Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2020 | $10M | Post-IPO | – | – | – |
| May 2010 | $45M | Series C | – | Excel Medical Ventures | |
| Sep 2009 | $10M | Series B | – | F-Prime Capital | |
| Aug 2008 | $15M | Series A | – | – | |
| Nov 2006 | $10.04M | Series A | – | – |
8 investors in total: 8 institutional.
Investors in Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include La Jolla Pharmaceutical, Flagship Pioneering and Excel Venture Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | cmea.com | - | |
- | – | mediphaseventure.com | - | |
US life sciences companies are invested in by Skyline Ventures. | – | skylineventures.com | Palo Alto, United States | |
Life sciences-focused venture capital firm | 1999 | flagshippioneering.com | Cambridge, United States | |
Investments in life sciences, technology, healthtech, and crypto sectors from global locations. | – | fprimecapital.com | - | |
Venture capital funding is provided by Fidelity-backed Fidelity Ventures. | – | fidelityventures.com | Boston, United States | |
Companies are built to apply transformative life science technologies. | – | emven.com | - | |
Developer of therapies for treating hemochromatosis & beta thalassemia | 1989 | lajollapharmaceutical.com | San Diego, United States |
Investor details for Tetraphase Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Tetraphase Pharmaceuticals
12 people are tracked at Tetraphase Pharmaceuticals (4 in leadership, 7 in board & advisors, 1 in team); the tracked headcount is 31.
| Name | Role | Group |
|---|---|---|
Paul Howard | Founder | Leadership |
Leo Yasinski | Executive Director of Strategy & Market Access | Leadership |
Nancy O'Neil, RAC | Associate Director, Regulatory Affairs | Leadership |
Olga Gilicky | Associate director analytical development | Leadership |
Steven Boyd | Director | Board & advisors |
Keith Maher | Director | Board & advisors |
Gerri Henwood | Director | Board & advisors |
L. Patrick Gage | Chairman | Board & advisors |
Garen Bohlin | Director | Board & advisors |
Jeffrey A. Chodakewitz | Director | Board & advisors |
John G. Freund | Director | Board & advisors |
Jay Coleman, M.H.A. | Regional Account Manager | Team |
Complete people profiles for Tetraphase Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Tetraphase Pharmaceuticals
5 dated milestones of Tetraphase Pharmaceuticals across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Tetraphase Pharmaceuticals is founded.
- Funding First funding round of $10.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $10.0M.
- Exit Acquired by La Jolla Pharmaceutical.
Competitors of Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sperotherapeutics.com | 2013 | Cambridge, United States | $114.7M | 46 | Therapeutics for drug-resistant bacterial infections are developed. | |
| nabriva.com | 2006 | Vienna, Austria | $193.08M | – | Pleuromutilin antibiotics are developed for MDR infections. | |
| melinta.com | 2000 | Morristown, United States | $186M | 290 | Developer of bacterial ribosome-targeting drugs for MDR infections | |
| iterumtx.com | 2015 | Dublin, Ireland | $78.1M | – | Developer of antibiotics for MDR infections | |
| aphage.com | 2016 | Bethesda, United States | $107.87M | 78 | Therapies for multi-drug resistant infections are developed using bacteriophages. | |
| cubist.com | 1993 | Lexington, United States | – | 895 | Pharmaceuticals for acute care bacterial infections are developed and commercialized. | |
| paratekpharma.com | 1996 | Boston, United States | $96.48M | 205 | Therapeutics for antimicrobial resistant infections are developed. | |
| locus-bio.com | 2015 | Raleigh, United States | $67.33M | 74 | Developer of therapeutics for infectious disease and inflammatory indications | |
| vedantabio.com | 2010 | Cambridge, United States | $350.49M | 71 | Therapeutics for infectious and autoimmune diseases are developed. | |
| allecra.com | 2013 | – | $44.44M | – | Antibiotics for multi-drug-resistant bacterial infections are developed. |
Detailed competitors of Tetraphase Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Tetraphase Pharmaceuticals
Websites that share an audience with Tetraphase Pharmaceuticals (tphase.com).
Websites whose visitors overlap most with Tetraphase Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
reactgroup.org | reactgroup.org | 100% | – | #738,151 | – |
hopkins-abxguide.org | hopkins-abxguide.org | 100% | – | #11,152,487 | – |
Latest news on Tetraphase Pharmaceuticals
Complete news archive for Tetraphase Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Tetraphase Pharmaceuticals
10 companies that operate in the same segment as Tetraphase Pharmaceuticals (Infectious Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Clinical diagnostics and drug discovery for immune diseases are provided. | 2009 | Seattle, Washington, United States | USD 419.15 M | USD 276.98 M | 619 | |
Vaccines for infectious diseases are developed using cell-free protein synthesis. | 2013 | Foster City, California, United States | USD 347 M | – | 414 | |
Portable PCR diagnostics for infectious diseases are developed. | 2010 | San Jose, California, United States | USD 386.33 M | – | – | |
Developing glucan synthase inhibitors for the treatment of fungal infections. | 1999 | Jersey City, New Jersey, United States | USD 62.65 M | USD 20.6 M | 28 | |
Sherlock Biosciences is focused on molecular diagnostics development. | 2019 | Watertown, United States | USD 111 M | – | 33 | |
Provider of diagnostic solutions for systemic infections | 2016 | San Francisco, California, United States | USD 191.47 M | – | 54 | |
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals was founded in 2006.
Tetraphase Pharmaceuticals is headquartered in Watertown, United States.
Tetraphase Pharmaceuticals is a funded company, having raised a total of $80.04M across 5 funding rounds to date. The company's 1st funding round was a Series A of $10.04M, raised on Nov 2006.
Tetraphase Pharmaceuticals has 31 employees.
Tetraphase Pharmaceuticals was founded in 2006 as a clinical-stage biopharmaceutical company based in Watertown, United States. Proprietary chemistry technology is employed to produce novel tetracycline analogs targeting multidrug-resistant infections. A library exceeding 2500 compounds has been assembled and is screened against bacterial targets. The lead candidate, Eravacycline, a fully synthetic fluorocycline antibiotic, is advanced in phase 3 trials for complicated intra-abdominal infections and complicated urinary tract infections.
Tetraphase Pharmaceuticals's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.
Tetraphase Pharmaceuticals has 8 investors. Key investors include La Jolla Pharmaceutical, Flagship Pioneering, Excel Venture Management, CMEA Capital, and Mediphase Venture Partners.
Yes. Tetraphase Pharmaceuticals was acquired by La Jolla Pharmaceutical in June 2020.